The histone variant H2A.X is a regulator of the epithelial–mesenchymal transition

Urbain Weyemi; Christophe E. Redon; Rohini Choudhuri; Towqir Aziz; Daisuke Maeda; Myriem Boufraqech; Palak R. Parekh; Taresh K. Sethi; Manjula Kasoji; Natalie Abrams; Anand Merchant; Vinodh N. Rajapakse; William M. Bonner

doi:10.1038/ncomms10711

Nature Communications (Feb 2016)

The histone variant H2A.X is a regulator of the epithelial–mesenchymal transition

Urbain Weyemi,
Christophe E. Redon,
Rohini Choudhuri,
Towqir Aziz,
Daisuke Maeda,
Myriem Boufraqech,
Palak R. Parekh,
Taresh K. Sethi,
Manjula Kasoji,
Natalie Abrams,
Anand Merchant,
Vinodh N. Rajapakse,
William M. Bonner

Affiliations

Urbain Weyemi: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Christophe E. Redon: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Rohini Choudhuri: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Towqir Aziz: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Daisuke Maeda: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Myriem Boufraqech: Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Palak R. Parekh: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Taresh K. Sethi: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
Manjula Kasoji: Center for Cancer Research Collaborative Bioinformatics Resource, National Cancer Institute
Natalie Abrams: Center for Cancer Research Collaborative Bioinformatics Resource, National Cancer Institute
Anand Merchant: Center for Cancer Research Collaborative Bioinformatics Resource, National Cancer Institute
Vinodh N. Rajapakse: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health
William M. Bonner: Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health

DOI: https://doi.org/10.1038/ncomms10711
Journal volume & issue: Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

The histone H2A variants are involved in DNA repair, gene regulation and cancer development. In this study, the authors unravel an additional role for H2A.X in the regulation of mesenchymal-like traits and activation of the EMT transcription factors, Slug and ZEB1, in colon cancer cells.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal